The study tests BNT327, an investigational drug administered via intravenous infusion, in combination with standard chemotherapy drugs like etoposide, carboplatin, paclitaxel, and topotecan. The goal ...

This study could significantly impact BioNTech’s stock performance and investor sentiment, especially if the results demonstrate a breakthrough in breast cancer treatment. The involvement of ...

In August 2025, BioNTech SE organized a Phase II study in participants with untreated extended-stage small-cell lung cancer (ES-SCLC) (Cohort 1) or small-cell lung cancer (SCLC) which has progressed ...

The gush of second quarter earnings reports is beginning to slow to a trickle, and with most of the reports in, the results have been mostly positive.

The gush of second quarter earnings reports is beginning to slow to a trickle, and with most of the reports in, the results have been mostly positive.

The gush of second quarter earnings reports is beginning to slow to a trickle, and with most of the reports in, the results have been mostly positive.

The gush of second quarter earnings reports is beginning to slow to a trickle, and with most of the reports in, the results have been mostly positive.

The gush of second quarter earnings reports is beginning to slow to a trickle, and with most of the reports in, the results have been mostly positive.